Evidence map›Paper›PMID 32138774›Full record

ArticleJournal of orthopaedic surgery and research2020

5-Aminolevulinic acid tumor paint and photodynamic therapy for myxofibrosarcoma: an in vitro study.

Shachar Kenan, Haixiang Liang, Howard J Goodman, Andrew J Jacobs, Amanda Chan, Daniel A Grande, Adam S Levin

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07038278 (5-AminoLevulinic Acid Aided Resection Margins in Sarcoma), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07038278 early_phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

5-AminoLevulinic Acid Aided Resection Margins in Sarcoma (5-ALARMS)

TypeinterventionalSponsorUniversity of Colorado, DenverRan2026 to 2028Enrolled20ConditionsSoft Tissue Sarcoma (STS)Arms5-ALA
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Shachar KenanDepartment of Orthopaedic Surgery, North Shore-Long Island Jewish Hospital, Northwell Health System, 270-05 76th Avenue, New Hyde Park, NY, 11040, USA.
Haixiang LiangOrthopaedic Research Laboratory, The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY, 11030, USA.
Howard J GoodmanDepartment of Orthopaedic Surgery, North Shore-Long Island Jewish Hospital, Northwell Health System, 270-05 76th Avenue, New Hyde Park, NY, 11040, USA.
Andrew J JacobsHofstra Northwell School of Medicine, 500 Hofstra University, Hempstead, NY, 11549, USA.
Amanda ChanMicroscopy Facility, The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY, 11030, USA.
Daniel A GrandeOrthopaedic Research Laboratory, The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY, 11030, USA.
Adam S LevinDepartment of Orthopaedic Surgery and Oncology, The Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD, 21287, USA. alevin25@jhmi.edu.
Feinstein Institute for Medical Research · USNorthwell Health · USHofstra University · USJohns Hopkins Medicine · US

Funding

H. Craig and Lora Treiber Orthopaedic Research Foundation NALong Island Jewish Medical Center NA
6 · The paper itself

Abstract

background5-Aminolevulinic acid (5-ALA), a fluorescent contrast agent, has been used for tumor paint and photodynamic therapy (PDT) for various tumors, but its use with soft tissue sarcomas is not well documented. Myxofibrosarcoma, a subtype of soft tissue sarcoma with a high local recurrence rate, may benefit from similar types of treatment. The purpose of this study was to analyze the effects of 5-ALA tumor paint and PDT on a myxofibrosarcoma cell line.

methodsTumor paint was assessed by exposing micromass pellets of human adipose-derived stromal (ADS) cells or myxofibrosarcoma (MUG-Myx1) cells to 5-ALA. Cell pellets were then visualized using a microscope at established excitation and emission wavelengths. Corrected total cell fluorescence was calculated per accepted protocols. Photodynamic therapy was similarly assessed by exposing ADS and MUG-Myx1 cells to 5-ALA, with subsequent analysis via flow cytometry and real-time confocal microscopy.

resultsThe use of 5-ALA tumor paint led to a selective fluorescence in MUG-Myx1 cells. Findings were confirmed by flow cytometry. Interestingly, flow cytometry results showed progressive selective cell death with increasing 5-ALA exposure as a result of the PDT effect. PDT was further confirmed using confocal microscopy, which revealed progressive cellular bubble formation consistent with advancing stages of cell death-a finding that was not seen in control ADS cells.

conclusions5-ALA tumor paint and PDT were successfully used on a human myxofibrosarcoma cell line (MUG-Myx1). Results from this study showed both selective fluorescent tagging and selective cytotoxicity of 5-ALA toward malignant myxofibrosarcoma cells, while sparing benign adipose control cells. This finding was further confirmed in a dramatic time-lapse video, visually confirming active, targeted cell death. 5-ALA's two-pronged application of selective tumor identification and cytotoxicity may transform surgical and medical approaches for treating soft tissue sarcomas.

Indexed as

Aminolevulinic AcidCell Line, TumorContrast MediaFibromaFibrosarcomaHumansMicroscopy, ConfocalPhotochemotherapyAminolevulinic AcidContrast Media5-Aminolevulinic acidMyxofibrosarcomaNeoadjuvant therapyPhotodynamic therapySarcomaTumor paint

Identifiers

PMID32138774
PMCPMC7059315
OpenAlexW3010049786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.